Cardiac Monitor Maker Raises Outlook, Delays Filing
Device makers should note that stronger wearable monitoring demand is offsetting softer legacy product sales and a later FDA filing.
Updated on Nov. 7, 2026 in Healthcare

iRhythm Holdings raised its 2026 revenue outlook to $890 million to $895 million after third-quarter revenue of $221.6 million, up nearly 15% from a year earlier. The company also no longer plans to submit its Zio MCT device to the FDA in 2026, now expecting a 2027 filing, which affects medical device makers and cardiac monitoring providers.
Why it matters
The higher outlook reflects stronger-than-expected demand for the Zio Monitor business, while the delayed Zio MCT filing pushes out a product launch timeline. For operators in medical technology and healthcare services, the split between a strong monitoring line and a slowing AT line shows how quickly product-mix shifts can move revenue.
iRhythm reported third-quarter revenue of $221.6 million, up nearly 15% from a year earlier, and lifted its 2026 revenue outlook to $890 million to $895 million. The company expects Zio AT revenue to fall about 10% in the fourth quarter, while the Zio Monitor business outperformed expectations.
The players
iRhythm Holdings
iRhythm Holdings is a medical technology company that makes wearable cardiac monitoring devices, including the Zio line of heart-rhythm monitors.
U.S. Food and Drug Administration
The FDA is the federal agency that reviews and clears medical devices before they can be marketed in the United States.
The details
Zio Monitor, a wearable heart-rhythm monitoring product, outperformed the company's expectations in the third quarter, offsetting flat year-over-year Zio AT revenue. Zio AT sales are expected to decline about 10% in the fourth quarter. Customer onboarding delays are expected to persist in the near term, which can slow the rate at which new orders convert into recognized revenue. iRhythm now plans to file its Zio MCT submission with the FDA in 2027 rather than in 2026.
Timeline
Q3 2026: third-quarter revenue reported at $221.6 million.
Q4 2026: Zio AT revenue expected to decline about 10%.
2026: revenue outlook raised; Zio MCT FDA filing no longer planned this year.
2027: Zio MCT FDA submission expected, with an adjusted EBITDA margin target of at least 15%.
Market Landscape
The Zio Monitor and Zio AT product lines are iRhythm's core cardiac monitoring offerings, and the divergence between them shapes near-term revenue. The delayed Zio MCT submission pushes the company's next product filing into 2027, extending its timeline relative to its prior plans.
Operators in medical device and cardiac monitoring should weigh the strength of wearable monitoring demand against slower onboarding and declining legacy product sales. Procurement and sales teams should plan for longer product-launch timelines when a regulatory filing slips into a later year.
The takeaway
For medical device operators, the key insight is that a strong monitoring line can carry revenue even as a legacy product declines. Track the timing of customer onboarding recovery and the next FDA filing milestone, since both determine when the company's guidance and product pipeline translate into results.
What happens next
iRhythm expects to submit its Zio MCT device to the FDA in 2027 and targets an adjusted EBITDA margin of at least 15% that year.
Further reading
For broader context on regulatory timelines and device makers, see the Healthcare coverage.




